Clarity Pharmaceuticals Ltd (ASX: CU6)
Australia
· Delayed Price · Currency is AUD
5.97
-0.09 (-1.49%)
Nov 21, 2024, 4:10 PM AEST
Clarity Pharmaceuticals Revenue
In the fiscal year ending June 30, 2024, Clarity Pharmaceuticals had annual revenue of 11.51M AUD with 17.41% growth. Clarity Pharmaceuticals had revenue of 6.09M in the half year ending June 30, 2024, with 66.73% growth.
Revenue
11.51M
Revenue Growth
+17.41%
P/S Ratio
141.72
Revenue / Employee
230.13K
Employees
50
Market Cap
1.91B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 22.18B |
ResMed Inc. | 6.93B |
Pro Medicus Limited | 161.50M |
Fisher & Paykel Healthcare Corporation Limited | 1.60B |
Cochlear Limited | 2.24B |
Sonic Healthcare Limited | 8.97B |
Ramsay Health Care Limited | 16.66B |
Telix Pharmaceuticals Limited | 645.68M |
Clarity Pharmaceuticals News
- 5 weeks ago - Rising Shares at Clarity Pharmaceuticals as it Launches Second Phase III Trial and Promotes Michelle Parker to CEO - CEOWORLD magazine
- 4 months ago - Three ASX companies jockeying to be the next biotech winners - The Australian Financial Review